http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#Head
http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#assertion
http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#provenance
http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#pubinfo
http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#assertion
http://purl.obolibrary.org/obo/DOID_11476
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_11476
http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB06643
http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#association
http://www.w3.org/2000/01/rdf-schema#label
prolia is a rank ligand rankl inhibitor indicated for treatment of postmenopausal women with osteoporosis at high risk for fracture 1 1 treatment to increase bone mass in men with osteoporosis at high risk for fracture 1 2 treatment of glucocorticoid induced osteoporosis in men and women at high risk for fracture 1 3 treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer 1 4 treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer 1 5 prolia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture or multiple risk factors for fracture or patients who have failed or are intolerant to other available osteoporosis therapy in postmenopausal women with osteoporosis prolia reduces the incidence of vertebral nonvertebral and hip fractures see clinical studies 14 1 prolia is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture or multiple risk factors for fracture or patients who have failed or are intolerant to other available osteoporosis therapy see clinical studies 14 2 prolia is indicated for the treatment of glucocorticoid induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7 5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months high risk of fracture is defined as a history of osteoporotic fracture multiple risk factors for fracture or patients who have failed or are intolerant to other available osteoporosis therapy see clinical studies 14 3 prolia is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer in these patients prolia also reduced the incidence of vertebral fractures see clinical studies 14 4 prolia is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer see clinical studies 14 5
http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB06643
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#provenance
http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#pubinfo
http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#sig
http://purl.org/nanopub/x/hasSignature
PESP4v3M9hvId4z2935Yb2LtKm43QdCqtQhnguNgyvecR5+PvWzuODiWQ+h5JmAkdmLiPHCxT1qk3DCj3WbuMghW1rTRj1FUKS4If5OjYVDz8NwhVAG28IQ9tuc53pY1bLCvN93LW9w5cJL+20HORXjUHJzQJPJdPqNyifutUSM=
http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4
http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4
http://purl.org/dc/terms/created
2021-07-03T14:58:51.850+02:00
http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs